

SuperSonic Imagine Installs Aixplorer® Ultrasound System at the Brust-Zentrum Breast Centre in Zürich, Switzerland

Aix-en-Provence, France, December 17th, 2015 - SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specializing in ultrasound medical imaging, today announced the installation of its Aixplorer® Ultrasound System at the Brust-Zentrum Breast Centre in Zürich, Switzerland. The Brust-Zentrum Breast Centre is a renowned multidisciplinary practice specializing in providing diagnosis and state-of-the-art treatment of breast lesions.

"I am very enthusiastic to offer to our patients the most advanced and reliable method of Elastography. The Aixplorer system is an excellent match for my daily practice: it is intuitive and easy to use. We are also pleased to have training support available, as needed, to provide patients with the highest quality of care for assessing breast lesions" commented Dr. Sibylle Dubach Schwizer from Brust-Zentrum Breast Centre.

SuperSonic Imagine's Aixplorer Ultrasound System is equipped with an UltraFast™ software platform, which has the capacity to acquire images 200 times faster than conventional ultrasound. The system is also equipped with ShearWave™ Elastography (SWE™) technology. SWE provides physicians a comprehensive, accurate and quantitative evaluation of tissue stiffness in real time via a color-coded map of elasticity in conjunction with a high quality two-dimensional ultrasound image of morphology. Tissue stiffness is an important criteria used by physicians to identify potentially malignant lesions.

The benefits of using the ShearWave technology for the diagnosis of breast lesions have been demonstrated in more than 60 peer-reviewed publications, including a multinational study of over 1,600 patients. The results showed that ShearWave Elastography, combined with conventional ultrasound criteria, allowed superior accuracy in the diagnosis of breast lesions and significantly reduced the number of false positive cases. By improving the accuracy of breast ultrasound, SuperSonic Imagine's SWE technology helps to reduce the number of unnecessary biopsies.

"Breast cancer is the most common cancer in women worldwide¹. We are committed to delivering innovation that provides significant clinical benefits and are passionate about our technology's ability to improve the diagnosis of breast cancer. Installing the Aixplorer system in a prominent practice such as the Brust-Zentrum Breast Centre speaks to the superior overall diagnostic experience Aixplorer brings to the medical community," said Jacques Souquet, Founder and Chief of Innovation Officer of SuperSonic Imagine.

1. Source: <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics>

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster

than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com

SuperSonic Imagine

Marketing & Communication
Emmanuelle Vella
emmanuelle.vella@supersonicimagine.com
+33 4 86 79 03 27

Blueprint Life Science Group

Investor Relations - US
Candice Knoll
cknoll@bplifescience.com
+1 415 375 3340 Ext. 4

NewCap

Investor Relations - EU
Pierre Laurent / Florent Alba
supersonicimagine@newcap.fr
+33 1 44 71 98 55

ComCorp

Media Relations
Adelaide Manester
amanester@comcorp.fr
+33 1 58 18 32 58 - +33 6 70 45 74 37

